News Mylan expects first US Herceptin biosimilar launch Deal with Roche paves way for near-copy of breast cancer blockbuster
News Roche breast cancer trial success could kill Puma's rival Perjeta trial success sends rival biotech's share price crashing.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Call for Roche to lower Kadcyla price further after NICE rej... Ruling could end funding for cancer drug in England.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Grail cancer test gets lukewarm backing from FDA adcomm FDA expert advisors voted in favour of Grail's Galleri blood test for detecting multiple cancers, but some expressed misgivings about its efficacy.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
